| gap-pubmed-20260410- | How does RGS6 deficiency mechanistically lead to α-synuclein accumulation in dop | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does intermittent versus continuous heat stress differentially affect circad | open | 0.72 | 0.00 | 2026-04-10 | 0 | | circadian-neurobiology |
| gap-pubmed-20260410- | How does BMAL1 mechanistically regulate the AMPK/mTOR/ULK1 autophagy pathway in | open | 0.77 | 0.00 | 2026-04-10 | 0 | | vascular-neurobiology |
| gap-pubmed-20260410- | How do computational predictions of EGCG binding to SIRT3, FOXO1, and PPARGC1A t | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does EGCG show superior neuroprotective potency compared to resveratrol desp | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does increased exosome release paradoxically worsen tau propagation despite | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do ESCRT components and Rab GTPases specifically regulate tau trafficking ve | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine whether tau is routed to lysosomal degradati | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can ELA pathway proteins serve as reliable diagnostic biomarkers given the high | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do autophagy markers show limited evidence of dysregulation despite clear ly | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the differential dysregulation patterns of ELA proteins in | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do ESCRT pathway defects occur in human tauopathy brains and correlate with dise | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does endolysosomal tau seed escape specifically enhance cytoplasmic tau aggr | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the precise molecular mechanisms by which ESCRT dysfunction causes endo | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does synaptic disassembly function as an early tipping point rather than jus | open | 0.78 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What determines the spatial and temporal sequence of signaling pathway disintegr | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do phase-transitioned stress granules mechanistically sequester nucleocytopl | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What design principles can overcome the complexity challenges in developing effe | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do apoE isoforms differentially affect Aβ-independent pathways in Alzheimer' | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific mechanisms underlie apoE4's acceleration of amyloid plaque formati | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific precision medicine approaches can effectively target APOE for AD t | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do Aβ-independent APOE pathways contribute to neurodegeneration and can they | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which APOE4 drives earlier and mor | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why have numerous phase 3 clinical trials failed despite advances in understandi | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the critical cellular and molecular processes beyond amyloid and tau th | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the relative contributions of APOE-mediated microglia/astrocyte respons | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does APOE mechanistically contribute to tau neurofibrillary degeneration ind | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do successful APOE-targeted therapies in mouse models fail to translate to h | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the relationship between lysosomal dysfunction and cholesterol metabolis | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does glial lipid efflux mechanistically reduce tau pathology and neurodegene | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which ApoE4 promotes glial lipid a | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does R136S mutation alter APOE4 protein structure or function to confer neur | resolved | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does heterozygous R136S protect against neurodegeneration and neuroinflammat | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the dose-dependent protective effects of the | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why are cell cycle genes upregulated in post-mitotic neurons during Parkinson's | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the shared mRNA dysregulation patterns across distinct neu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the >60% prevalence of anxiety/depression comorbidity specifical | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do >30 defective pharmagene variants per patient mechanistically interact to | open | 0.78 | 0.00 | 2026-04-10 | 0 | | pharmacogenomics |
| gap-pubmed-20260410- | How do bispecific antibodies achieve more uniform brain distribution compared to | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie TfR1-mediated reduction in ARIA compared to conventiona | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is clinical evidence insufficient to establish LRP1's contribution to AD dev | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do circadian disruptions in lipid metabolism specifically contribute to brai | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which circadian clock genes regula | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-pubmed-20260410- | How do BMAL1 and CLOCK specifically regulate microglial activation states in the | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which circadian disruption affects | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the spatial reorganization of HK that supports proliferative met | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does disrupted HK-VDAC interaction mechanistically drive neurodegeneration v | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific post-translational modifications and signaling pathways regulate H | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What shared glucose metabolism regulatory mechanisms explain flavonoids' dual an | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How can the dynamic nature of microglial metabolism be effectively monitored and | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |